← All trials
NCT01493778
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2012
- Primary completion
- Feb 13, 2017
- Completion date
- Jun 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.